Windlas Biotech (NSE:WINDLAS) YoY EBITDA Growth: -0.08% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
88 GF Score
Price ₹1,129.25
GF Value ₹988.65
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Windlas Biotech YoY EBITDA Growth?

Windlas Biotech NSE:WINDLAS -0.01% 88 YoY EBITDA Growth is -0.08% as of Jun. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 88/100 and a GF Value™ of ₹988.65 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Windlas Biotech's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -0.08%.

Windlas Biotech's EBITDA per Share for the three months ended in Jun. 2026 was ₹14.98.

Windlas Biotech YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech YoY EBITDA Growth Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial 161.14 12.46 35.33 20.88 8.23

Windlas Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.48 14.83 -0.09 -3.59 -0.08
NSE:WINDLAS
88GF Score
Windlas Biotech Ltd NSE:WINDLAS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Windlas Biotech's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(57.442-53.072)/ | 53.072 |
=8.23 %

Windlas Biotech's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(14.984-14.996)/ | 14.996 |
=-0.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -0.08% mean?
Windlas Biotech (NSE:WINDLAS) has a YoY EBITDA Growth of -0.08% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Windlas Biotech and its competitors.
Is Windlas Biotech's YoY EBITDA Growth too high?
Windlas Biotech's current YoY EBITDA Growth is -0.08%. Overall, Windlas Biotech has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's YoY EBITDA Growth compare to ZTS?
Windlas Biotech's YoY EBITDA Growth of -0.08% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Windlas Biotech and its competitors. Windlas Biotech's current YoY EBITDA Growth is -0.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹988.65, compared to a current price of ₹1,129.25 — trading 14.2% above its estimated fair value. The current YoY EBITDA Growth is -0.08%. Windlas Biotech's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current YoY EBITDA Growth is -0.08% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be overvalued. The current stock price of ₹1,129.25 is trading 14.2% above its estimated GF Value™ of ₹988.65. GuruFocus considers Windlas Biotech to be Modestly Overvalued.

Key valuation signals for NSE:WINDLAS:

  • YoY EBITDA Growth: -0.08%
  • GF Value™: ₹988.65 vs. price of ₹1,129.25 (14.2% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
88GF Score

Get the complete analysis for NSE:WINDLAS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,129.25
Price
₹988.65
GF Value